27-Mar-2019
Publication in Neurology®: Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome Publication in Neurology®: Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome

23-Jun-2016
Poster at Rettsyndrome.org 2016 Rett Syndrome Symposium Poster at Rettsyndrome.org 2016 Rett Syndrome Symposium
Improving outcome measures for Rett Syndrome (RTT) clinical trials: Development of CSS/MBA change indexes to assess treatment outcome

22-Jun-2016
Presentation by Daniel Glaze, MD, at Rettsyndrome.org 2016 Rett Syndrome Symposium Presentation by Daniel Glaze, MD, at Rettsyndrome.org 2016 Rett Syndrome Symposium
Past, Present and Future: A program to develop and establish Trofinetide as a safe and effective treatment for Rett syndrome

12-May-2016
Presentation at 6th Annual TBI Conference, Washington DC Presentation at 6th Annual TBI Conference, Washington DC
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients with Traumatic Brain Injury

22-Apr-2015
Poster at American Academy of Neurology 2015 Annual Meeting Poster at American Academy of Neurology 2015 Annual Meeting
NNZ-2566: A Novel, Experimental Treatment for Rett Syndrome

15-May-2014
Poster at International Meeting for Autism Research (IMFAR) Poster at International Meeting for Autism Research (IMFAR)
Improving outcome measures for Rett Syndrome (RTT) clinical trials: the development of RTT-specific anchors for the Clinical Global Impression Scale

30-Sep-2013
Poster at 2013 FRAXA Investigators Meeting Poster at 2013 FRAXA Investigators Meeting
The Impact of NNZ-2591 on the fmr1 Knockout Mouse Model of Fragile X Syndrome

4-Apr-2013
Poster at American Neuropsychiatric Association 2013 Annual Meeting Poster at American Neuropsychiatric Association 2013 Annual Meeting
The Impact of NNZ-2566 on the fmr1 Knockout Mouse Model of Fragile X Syndrome

1-Aug-2012
Presentation by Dr Mike Snape at ICare4Autism 2012 International Autism Conference Presentation by Dr Mike Snape at ICare4Autism 2012 International Autism Conference
NNZ-2566 - Rationale for use in Autism Spectrum Disorders